ID   SW1573/2R120
AC   CVCL_WG70
SY   SW-1573/2R120; 2R120
DR   cancercelllines; CVCL_WG70
DR   Wikidata; Q98132917
RX   CelloPub=CLPUB00485;
RX   PubMed=1353703;
RX   PubMed=1974823;
RX   PubMed=9256160;
CC   Population: Caucasian.
CC   Doubling time: 42 hours (PubMed=9256160).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C2923; Minimally invasive lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A5BA ! SW1573/S1
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 05-10-23; Version: 8
//
RX   CelloPub=CLPUB00485;
RA   Kuiper C.M., Broxterman H.J., Baas F., Schuurhuis G.J., Haisma H.J.,
RA   Scheffer G.L., Lankelma J., Pinedo H.M.;
RT   "Drug transport variants without P-glycoprotein overexpression from a
RT   human squamous lung cancer cell line after selection with doxorubicin.";
RL   J. Cell. Pharmacol. 1:35-41(1990).
//
RX   PubMed=1353703;
RA   Nieuwint A.W.M., Baas F., Wiegant J., Joenje H.;
RT   "Cytogenetic alterations associated with P-glycoprotein- and
RT   non-P-glycoprotein-mediated multidrug resistance in SW-1573 human lung
RT   tumor cell lines.";
RL   Cancer Res. 52:4361-4371(1992).
//
RX   PubMed=1974823;
RA   Baas F., Jongsma A.P.M., Broxterman H.J., Arceci R.J., Housman D.E.,
RA   Scheffer G.L., Riethorst A., van Groenigen M., Nieuwint A.W.M.,
RA   Joenje H.;
RT   "Non-P-glycoprotein mediated mechanism for multidrug resistance
RT   precedes P-glycoprotein expression during in vitro selection for
RT   doxorubicin resistance in a human lung cancer cell line.";
RL   Cancer Res. 50:5392-5398(1990).
//
RX   PubMed=9256160; DOI=10.1016/S0006-2952(97)82448-3;
RA   van Triest B., Pinedo H.M., Telleman F., van der Wilt C.L., Jansen G.,
RA   Peters G.J.;
RT   "Cross-resistance to antifolates in multidrug resistant cell lines
RT   with P-glycoprotein or multidrug resistance protein expression.";
RL   Biochem. Pharmacol. 53:1855-1866(1997).
//